TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9065535

Group type: EXPERIMENTAL
Intervention: Chronic alcoholism
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 1 to 25 g/day
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 26 to 50 g/day
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 51 to 100 g/day
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol 101 to 200 g/day
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Average daily intake of absolute alcohol >200 g/day
Number of subjects: 237
Study: 8424288

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 50% oxygen: 50% nitrous oxide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 30% oxygen: 70% nitrous oxide
Number of subjects: 75
Study: 2870722

Group type: EXPERIMENTAL
Intervention: Ipecac-induced emesis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Gastric lavage
Number of subjects: 18
Study: 29755621

Group type: EXPERIMENTAL
Intervention: Expectation increasing (EI) group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Baseline (BL) group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: No expectation intervention (NoEI) group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Expectation decreasing (ED) group
Number of subjects: 72
Study: 27380615

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% levobupivacaine intraperitoneally
Number of subjects: 73

Group type: COMPARATOR
Intervention: 10 mL of 0.9% normal saline (placebo)
Number of subjects: 73
Study: 25127887

Group type: EXPERIMENTAL
Intervention: Intervention group with additional monitoring by Tvis levels
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-intervention group (control) treated conservatively
Number of subjects: 64
Study: 22560916

Group type: EXPERIMENTAL
Intervention: Optimized AVD (AV Opt group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Empiric AVD of 110 ms (AV Fixed group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CRT (both groups)
Number of subjects: 51
Study: 20530806

Group type: EXPERIMENTAL
Intervention: Rapid rises in haemoglobin (Hgb)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA) dose increases
Number of subjects: 154

Group type: COMPARATOR
Intervention: Hgb deflect(neg) and ESA dose decreases
Number of subjects: 154
Study: 17951095

Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glides (SNAGs)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (detuned laser)
Number of subjects: 34
Study: 12866834

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 5 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Formula feeding (independent choice)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Breast examination
Number of subjects: 80
Study: 11128667

Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: MACTAR questionnaire
Number of subjects: 155
Study: 8773423

Group type: EXPERIMENTAL
Intervention: Detailed structured pretreatment counseling
Number of subjects: 421

Group type: COMPARATOR
Intervention: Routine counseling
Number of subjects: 421
Study: 1611971

Group type: EXPERIMENTAL
Intervention: Optec inlay
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hi-Ceram inlay
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Coltene composite inlay
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ceramic inlays
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ceramic and composite inlays
Number of subjects: 73
Study: 29506743

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14236

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14236
Study: 27846903

Group type: EXPERIMENTAL
Intervention: Proton therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study: 24001888

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study: 24163957

Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D supplements (500 mg carbonate calcium plus 200 IU vitamin D3) for 9 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 20858943

Group type: EXPERIMENTAL
Intervention: Specified describing style in accordance with ATLAS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional method used in clinic
Number of subjects: 26
Study: 18513691

Group type: EXPERIMENTAL
Intervention: Central pancreatic-head resection (CPHR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quality-of-life (QOL) assessment after CPHR
Number of subjects: 100
Study: 16167418

Group type: EXPERIMENTAL
Intervention: Triple combination (TC) cream
Number of subjects: 585
Study: 14603516

Group type: EXPERIMENTAL
Intervention: Divalproex sodium with higher pH and sodium lauryl sulphate (SLS) in dissolution medium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalproex sodium with lower pH and higher SLS concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New testing conditions using USP Apparatus II at 100 rpm in 0.1 N HCl followed by 0.05 M phosphate buffer with 75 mM SLS
Number of subjects: 0
Study: 10935667

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 9060789

Group type: EXPERIMENTAL
Intervention: Lidocaine spray applied in the surgical wound
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine pain relief (not specified)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nurses' ability to predict pain
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients' ability to predict pain
Number of subjects: 60

Group type: COMPARATOR
Intervention: Age as a factor in pain perception
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preoperative anxiety
Number of subjects: 60

Group type: COMPARATOR
Intervention: Malignant diagnoses
Number of subjects: 60
Study: 2052637

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral antibiotic
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Parenteral antibiotics
Number of subjects: 48
Study: 6829321

Group type: EXPERIMENTAL
Intervention: Amoxycillin 1000 mg twice a day for three days
Number of subjects: 215

Group type: COMPARATOR
Intervention: Co-trimazine 90 mg/sulphadiazine 410 mg, 2 tablets initially, then 1 tablet twice daily for three days
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 215

Group type: COMPARATOR
Intervention: Co-trimazine
Number of subjects: 215
Study: 30795944

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 104
Study: 29990488

Group type: EXPERIMENTAL
Intervention: Simtuzumab 75 mg
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Simtuzumab 125 mg
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Simtuzumab 200 mg
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Simtuzumab 700 mg
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 27091604

Group type: EXPERIMENTAL
Intervention: CHW-assisted HBHRT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (independent HBHRT)
Number of subjects: 60
Study: 24865417

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 10 Hz (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham intervention (n = 12)
Number of subjects: 24
Study: 22278631

Group type: EXPERIMENTAL
Intervention: Test formulation of leflunomide 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of leflunomide 20 mg
Number of subjects: 24
Study: 20832344

Group type: EXPERIMENTAL
Intervention: SPECT (n=104)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: DE (n=100)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Both SPECT and DE
Number of subjects: 204
Study: 16439867

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa (PEG-IFN) with ribavirin (R)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard interferon alfa (IFN) with ribavirin (R)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 108
Study: 12921983

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10711438

Group type: EXPERIMENTAL
Intervention: Single 52‐Fr Maloney dilation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Endoscopic biopsy of Schatzki's ring (four quadrant biopsy)
Number of subjects: 26
Study: 9373419

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for psychosis, individualised, lasting nine months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 60
Study: 1610419

Group type: EXPERIMENTAL
Intervention: solution gel (1% diclofenac)
Number of subjects: 12

Group type: COMPARATOR
Intervention: emulsion gel (1% diclofenac)
Number of subjects: 12
Study: 3859953

Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin gel for cervical priming
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Extra-amniotic prostaglandin gel for labour induction
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Systemic administration of PG
Number of subjects: 64
Study: 31135178

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 59

Group type: COMPARATOR
Intervention: Child Life (CL) distraction
Number of subjects: 59

Group type: COMPARATOR
Intervention: Television (TV) distraction
Number of subjects: 59
Study: 28230324

Group type: EXPERIMENTAL
Intervention: Food-based diet (FD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Meal-replacement plan (MRP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both diets (FD and MRP)
Number of subjects: 60
Study: 25891304

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg) + placebo
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ipilimumab monotherapy
Number of subjects: 142
Study: 23902407

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri ATCC 55730 (1 × 10(8) CFU)
Number of subjects: 232
Study: 21211053

Group type: EXPERIMENTAL
Intervention: Educational program involving an in-service for centre staff, distribution of educational materials to parents, a parent workshop demonstrating restraint use, subsidised restraints for parents in need, and vouchers for a free restraint checking service.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 28
Study: 19953806

Group type: EXPERIMENTAL
Intervention: Indirect instruction with 'The Smiling Robot' and periodic reinforcement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indirect instruction with 'The Smiling Robot' without periodic reinforcement
Number of subjects: 40
Study: 16455814

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 or 100 mg) during hypoxic exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo during hypoxic exercise
Number of subjects: 10
Study: 15057252

Group type: EXPERIMENTAL
Intervention: Regression of ECG LVH (defined as a >/=25% decrease in Cornell product)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: No significant change in ECG LVH (defined as a <25% decrease)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Progression of ECG LVH (defined as an increase)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Regression of ECG LVH
Number of subjects: 584

Group type: COMPARATOR
Intervention: No significant decrease in ECG LVH
Number of subjects: 584

Group type: COMPARATOR
Intervention: Progression of ECG LVH
Number of subjects: 584
Study: 12495832

Group type: EXPERIMENTAL
Intervention: Decrease in sodium intake (100 mmol/24-hour)
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Increase in potassium intake (50 mmol/24-hour)
Number of subjects: 873
Study: 9843861

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Naltrexone (N)
Number of subjects: 10
Study: 7867112

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg.kg‐1 administered into the pulmonary artery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg.kg‐1 administered into the right atrium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg.kg‐1 administered into a peripheral vein
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vecuronium into the pulmonary artery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vecuronium into the right atrium
Number of subjects: 120
Study: 2474049

Group type: EXPERIMENTAL
Intervention: Cod liver oil (20 ml d‐1 for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no cod liver oil)
Number of subjects: 18
Study: 950801

Group type: EXPERIMENTAL
Intervention: Prednisone and cyclophosphamide combined
Number of subjects: 39

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 39
Study: 31285784

Group type: EXPERIMENTAL
Intervention: 600 mg/day alpha-lipoic acid (ALA)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 135
Study: 28552830

Group type: EXPERIMENTAL
Intervention: Intervention to improve communication between clinicians and families of critically ill patients
Number of subjects: 181
Study: 26500082

Group type: EXPERIMENTAL
Intervention: 0.25 g/d EPA + DHA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5 g/d EPA + DHA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.0 g/d EPA + DHA
Number of subjects: 20
Study: 22885882

Group type: EXPERIMENTAL
Intervention: Symbiotic mixture (Probinul, 5 g bid)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 64
Study: 21477675

Group type: EXPERIMENTAL
Intervention: TDV-TDV-TDV group (three TDV vaccinations at months 0, 3.5, and 12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TyVi-TDV-TDV group (licensed typhoid vaccination at month 0 and TDV at months 3.5 and 12)
Number of subjects: 0
Study: 19235738

Group type: EXPERIMENTAL
Intervention: Candy Smell Test (CST, 23 aromatized sorbitol candies)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Sniffin' Sticks test
Number of subjects: 353
Study: 16239279

Group type: EXPERIMENTAL
Intervention: Alkalosis (NaHCO3, 0.3 g kg(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CaCO3)
Number of subjects: 9
Study: 15523557

Group type: EXPERIMENTAL
Intervention: Herbal-based dentifrice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11716995

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone (Livial, Organon)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (2 mg lactose)
Number of subjects: 20
Study: 9068152

Group type: EXPERIMENTAL
Intervention: Wet-suit condition
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bathing-suit condition
Number of subjects: 13
Study: 7711419

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily) from days 1-24
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg daily) from days 11-21
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg single dose) on day 43
Number of subjects: 7
Study: 3415885

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 3 or 4 ml
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2 or 3 ml
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.5% bupivacaine 2 ml
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.75% bupivacaine 1.3 ml
Number of subjects: 28

Group type: COMPARATOR
Intervention: 10 mg dose of both solutions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 15-20/22.5 mg doses
Number of subjects: 28
Study: 30552747

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Diabetes support group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 48
Study: 28540538

Group type: EXPERIMENTAL
Intervention: Health Promotion (HP) program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Frailty Intervention (FI)
Number of subjects: 32
Study: 24077970

Group type: EXPERIMENTAL
Intervention: Adherence questionnaire asking about specific antiretroviral medication
Number of subjects: 6836

Group type: COMPARATOR
Intervention: Adherence questionnaire asking about HIV medicines as a group
Number of subjects: 6836
Study: 22244645

Group type: EXPERIMENTAL
Intervention: iRoot SP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epiphany
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MTA Fillapex
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moist condition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wet condition
Number of subjects: 80
Study: 18037080

Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 3994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3994
Study: 16286437

Group type: EXPERIMENTAL
Intervention: Divalproex sodium at a target dose of 750 mg/day (mean dose 800 mg/day) for 6 weeks
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 153
Study: 12402728

Group type: EXPERIMENTAL
Intervention: Prophylactic ondansetron 100 micrograms kg‐1 i.v.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Early symptomatic treatment with placebo
Number of subjects: 150
Study: 10549927

Group type: EXPERIMENTAL
Intervention: Factor IX complex concentrate (FIXCC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both groups (FFP and FIXCC)
Number of subjects: 13
Study: 7562235

Group type: EXPERIMENTAL
Intervention: Zinc picolinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2360063

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 0
Study: 6107409

Group type: EXPERIMENTAL
Intervention: Zinc therapy (zinc chloride added to the dialysate for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (added to the dialysate)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31050279

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 28251935

Group type: EXPERIMENTAL
Intervention: SIPsmartER intervention group
Number of subjects: 292

Group type: COMPARATOR
Intervention: MoveMore control group
Number of subjects: 292
Study: 28410176

Group type: EXPERIMENTAL
Intervention: SunProtect educational program delivered through a touch-screen tablet to 84 participants.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: SunProtect educational program delivered through a touch-screen tablet.
Number of subjects: 170
Study: 23645393

Group type: EXPERIMENTAL
Intervention: 12W endovenous laser ablation (intermittent laser withdrawal)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 14W endovenous laser ablation (continuous laser withdrawal)
Number of subjects: 76
Study: 21733215

Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioural intervention (overcoming anorexia online) with limited clinician supportive guidance
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual support from the UK patient and carer organization Beat
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioural intervention
Number of subjects: 64
Study: 19690352

Group type: EXPERIMENTAL
Intervention: Nerve fibre detection in endometrial biopsy
Number of subjects: 99
Study: 17920552

Group type: EXPERIMENTAL
Intervention: Novel viral vectors with reduced capacity to stimulate an adaptive immune response or become invisible to the immune system after delivery of the vector genome.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods to steer the immune response away from cytotoxic responses or induce tolerance to gene therapy products.
Number of subjects: 0
Study: 16934684

Group type: EXPERIMENTAL
Intervention: Energy restriction (20 kcal/kg) with whey or casein supplement (40 g/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Energy restriction (20 kcal/kg)
Number of subjects: 20
Study: 14616407

Group type: COMPARATOR
Intervention: Voriconazole (3 mg kg‐1) administered once daily on days 1 and 12, and every 12 h on days 3‐11 (Study A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Voriconazole (loading dose 6 mg kg‐1 twice on day 1, then 3 mg kg‐1 twice daily on days 2‐9, and once at 3 mg kg‐1 on day 10) (Study B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Study A and Study B)
Number of subjects: 30
Study: 10688417

Group type: EXPERIMENTAL
Intervention: Steroid group (1 g of methylprednisolone intravenously administered two hours before operation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 20
Study: 9005140

Group type: EXPERIMENTAL
Intervention: Collar and cuff shoulder immobilization
Number of subjects: 67

Group type: COMPARATOR
Intervention: No shoulder immobilization (control)
Number of subjects: 67
Study: 1913367

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6613236

Group type: EXPERIMENTAL
Intervention: 0.4 mg SIN 1
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31745601

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 1649